Corporate Sponsorship
Our partners share our passion for accelerating progress and improving patient outcomes. By supporting the Cholangiocarcinoma Foundation, Industry partners drive progress while strengthening bonds with their stakeholders, clients, and communities. We build corporate partnerships based on shared values to advance the goals of both organizations.
The 2024 Cholangiocarcinoma Foundation Annual Conference will take place April 17 -19th in Salt Lake City, Utah. It is the only global conference where cholangiocarcinoma (CCA) researchers and clinicians come together with patients and caregivers to share the latest science and work toward solutions for this deadly disease. Not only are the latest research and clinical advances shared, but clinicians and researchers have dedicated opportunities to engage directly with patients to identify and solve the problems affecting patients and their caregivers.
The International Cholangiocarcinoma Research Network (ICRN) Virtual Advisory Board Program is a highly engaged, multidisciplinary network of clinicians and investigators focused on cholangiocarcinoma. Comprising the world’s foremost clinical, translational, and basic science experts in this rare cancer, ICRN membership includes more than 200 experts from 90 institutions in 16 countries. The ICRN Advisory Board is a high-impact engagement with Key Opinion Leaders selected from the membership of the ICRN. It is a tool for gaining insight, feedback, interaction, and answers from the top experts and knowledge leaders in cholangiocarcinoma. Any company with an interest in cholangiocarcinoma — whether in drug development, drug repurposing, clinical trial management, genomic or genetic testing, patient and real-world data, or patient services and education—can benefit from an ICRN Advisory Board. Companies gain valuable feedback from professionals and patient advocates.
Instead of going to third-party advisory board facilitators, the funds for ICRN Industry Forums advance the Foundation’s mission and contribute to the development of cholangiocarcinoma science.
The Industry Council (IC) offers a collaborative forum for ongoing engagement and building stronger partnerships in areas of mutual interest. IC helps to elevate your company’s profile within the CCA community. Members provide input and recommendations on IC meeting topics and related projects, engage in annual opportunities for the IC to customize a query of the CCF Patient Registry, and conduct one patient survey with CCF. Members also receive priority access to conducting an educational clinical trial patient webinar and priority booth selection at the CCF Annual Conference, and IC recognition on CCF emails, press release(s), and online channels.
The CCF Fellowship Program supports early-career researchers worldwide, focusing on the study of cholangiocarcinoma. To date, nearly $2 million has been awarded for raising awareness about cholangiocarcinoma and inspiring innovative, quality research. The Cholangiocarcinoma Foundation chooses grant recipients carefully to ensure that they will build working relationships between researchers, institutions, and industry and share information, samples, and expertise with others in the field.
The CCF Newly Diagnosed Program supports patients and caregivers by connecting with each person following their cholangiocarcinoma diagnosis. Participants receive essential information such as CCA specialists, second opinions, biomarker testing, and vital resources for newly diagnosed patients through their entire cancer journey, including treatment options.
The International Cholangiocarcinoma Patient Registry represents a collaborative effort and opportunity for CCF to connect with our larger global patient community to further knowledge of cholangiocarcinoma. Its mission is to assist, accelerate and support research into earlier and more comprehensive diagnosis; life-extending therapies and treatments; new and repurposed drug trials; protocols and medications addressing debilitating treatment side-effects; possible end-stage complications; and ultimately, efforts leading to a cure for cholangiocarcinoma. The Vision of the patient registry is to collect bile duct cancer patient information about the incidence and prevalence of cholangiocarcinoma and related disorders and also assist in the screening of appropriate participants for research studies and clinical trials.
Clinical Trial Webinars are an ideal way to share information about your company, drug(s), and the latest information and developments with the broader CCA community.
TeamCCF sponsorship opportunities are available for companies interested in gaining greater exposure among the global CCA community by supporting athletic events to benefit CCF. Those events include Moving for the Cure, a unique athletic event that raises funding annually from participants who choose to ride, bike, or run to fund research for CCA. Virtual Turkey Trot Run/Bike/Walk Event that takes place during the week of Nov. 21-27.
Biomarkers Matter is a testing program created to help patients, caregivers, and healthcare professionals better understand the genomic and molecular drivers of CCA to help open the door to personalized treatment options, including access to clinical trials that may give patients a chance to live well and longer.
If you would like to receive more information on industry and corporate partnership opportunities with the Cholangiocarcinoma Foundation, please contact Kourtney Sanchez, Chief Development Officer, at 630.286.0418 or kourtney.sanchez@curecca.org.